HS-410

Current Status: cGMP Manufacturing Ongoing

Heat Biologics has developed an ImPACT-based drug for the treatment of patients with advanced bladder cancer.  cGMP manufacturing of HS-410 is currently underway and Heat expects to initiate Phase I clinical trials with this drug against advanced bladder cancer in Q2-2012.